News – Page 24 – Endpoints News

LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drug

Last month

Inspirna, which was preparing for a Phase 3 cancer trial, has folded

Last month

Alphabet’s Isomorphic Labs raises $600M in biotech’s largest round of 2025

Last month

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class

Last month

BiomX’s phage therapy succeeds in Phase 2 diabetic bone infection study

Last month

Exclusive: SV Health debuts Parkinson's biotech with backing from AbbVie and others

Last month

Vertex’s second-generation diabetes cell therapy fails early-stage study

Last month

HHS cuts and more from DC; Lyndra winds down; 23andMe files for bankruptcy; and more

Last month

FDA's Peter Marks resigns, says he won't accept Kennedy's 'misinformation and lies'

2 months ago

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

2 months ago

Lykos’ interim CEO is set to step down

2 months ago

Bluebird gets new M&A bid, seeking to top private equity offer

2 months ago

Judge tosses Amgen's challenge to Colorado drug review board, says suit is 'too speculative'

2 months ago

At long last, Novartis’ radiopharma drug Pluvicto gets an expanded label

2 months ago

FDA approves Sanofi's RNAi drug for hemophilia A and B

2 months ago

J&J beats Viatris in patent fight over its antipsychotic drug, staving off competition

2 months ago

CHMP recommends seven label expansions and one new approval, rejects Lilly Alzheimer's drug

2 months ago

Milestone's shares dive after FDA again rejects drug for abnormal heart rhythm

2 months ago

DBV’s financing for peanut allergy patch; Eisai divests proton pump inhibitor in China

2 months ago

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects

2 months ago

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

2 months ago

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

2 months ago

On the heels of staff cuts, CRISPR Therapeutics COO departs; Changes galore at Bicycle

2 months ago

Before Alumis went public via IPO, it tried doing a reverse merger with Acelyrin

2 months ago

First page Previous page 21 22 232425 26 27 Next page Last page